Scholar Rock (SRRK)

Executive Summary

Scholar Rock is a biopharmaceutical company focused on developing innovative therapies targeting the transforming growth factor beta (TGFβ) superfamily, with a core expertise in the biology of latent growth factors. The company's lead product candidate, apitegromab (SRK-015), is a selective inhibitor of myostatin activation, designed to improve muscle function in patients with spinal muscular atrophy (SMA). Positive Phase 2 data have shown clinically meaningful improvements in motor function, and the company has initiated pivotal Phase 3 trials. Beyond neuromuscular disease, Scholar Rock is expanding its pipeline into oncology with SRK-181, a latent TGFβ1 activator inhibitor, currently in Phase 1 clinical development. With a seasoned management team and a strong cash position, Scholar Rock is well-positioned to achieve key clinical milestones and potentially bring its first therapy to market.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on apitegromab BLA for spinal muscular atrophy70% success
• Q4 2026Phase 2 data readout for apitegromab in other neuromuscular indications60% success
• Q1 2027Phase 1 dose-escalation data for SRK-181 in oncology50% success